These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 12414642

  • 21. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW.
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [Abstract] [Full Text] [Related]

  • 22. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
    Hendrikx JJ, Lagas JS, Song JY, Rosing H, Schellens JH, Beijnen JH, Rottenberg S, Schinkel AH.
    Int J Cancer; 2016 Feb 01; 138(3):758-69. PubMed ID: 26297509
    [Abstract] [Full Text] [Related]

  • 23. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel.
    Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, Kim SW, Kim KH, Lee MG.
    Eur J Pharmacol; 2010 Feb 10; 627(1-3):92-8. PubMed ID: 19903471
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
    Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O.
    Invest New Drugs; 2004 Aug 10; 22(3):219-29. PubMed ID: 15122069
    [Abstract] [Full Text] [Related]

  • 25. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O.
    Cancer Chemother Pharmacol; 2002 Apr 10; 49(4):322-8. PubMed ID: 11914912
    [Abstract] [Full Text] [Related]

  • 26. Enhanced oral bioavailability of docetaxel by coadministration of cyclosporine: quantitation and role of P-glycoprotein.
    Chiou WL, Wu TC, Ma C, Jeong HY.
    J Clin Oncol; 2002 Apr 01; 20(7):1951-2; author reply 1952. PubMed ID: 11919259
    [No Abstract] [Full Text] [Related]

  • 27. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
    Shaik N, Giri N, Pan G, Elmquist WF.
    Drug Metab Dispos; 2007 Nov 01; 35(11):2076-85. PubMed ID: 17709369
    [Abstract] [Full Text] [Related]

  • 28. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.
    Oostendorp RL, Buckle T, Lambert G, Garrigue JS, Beijnen JH, Schellens JH, van Tellingen O.
    Invest New Drugs; 2011 Oct 01; 29(5):768-76. PubMed ID: 20390333
    [Abstract] [Full Text] [Related]

  • 29. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y, Ohtsuki S, Kamiie J, Terasaki T.
    J Pharmacol Exp Ther; 2011 Nov 01; 339(2):579-88. PubMed ID: 21828264
    [Abstract] [Full Text] [Related]

  • 30. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
    Li X, Choi JS.
    Int J Pharm; 2007 Jun 07; 337(1-2):188-93. PubMed ID: 17267149
    [Abstract] [Full Text] [Related]

  • 31. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
    Kivistö KT, Zukunft J, Hofmann U, Niemi M, Rekersbrink S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm MF.
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug 07; 370(2):124-30. PubMed ID: 15322734
    [Abstract] [Full Text] [Related]

  • 32. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF.
    J Pharmacol Exp Ther; 2009 Sep 07; 330(3):956-63. PubMed ID: 19491323
    [Abstract] [Full Text] [Related]

  • 33. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
    Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH.
    Cancer Res; 2003 Mar 15; 63(6):1339-44. PubMed ID: 12649196
    [Abstract] [Full Text] [Related]

  • 34. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Eur J Pharm Biopharm; 2019 Mar 15; 136():120-130. PubMed ID: 30660696
    [Abstract] [Full Text] [Related]

  • 35. Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.
    Joseph B, Bhargava KK, Malhi H, Schilsky ML, Jain D, Palestro CJ, Gupta S.
    Eur J Nucl Med Mol Imaging; 2003 Jul 15; 30(7):1024-31. PubMed ID: 12536246
    [Abstract] [Full Text] [Related]

  • 36. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.
    Jonker JW, Wagenaar E, van Deemter L, Gottschlich R, Bender HM, Dasenbrock J, Schinkel AH.
    Br J Pharmacol; 1999 May 15; 127(1):43-50. PubMed ID: 10369454
    [Abstract] [Full Text] [Related]

  • 37. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B.
    Drug Metab Dispos; 2009 May 15; 37(5):946-55. PubMed ID: 19225039
    [Abstract] [Full Text] [Related]

  • 38. In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
    Rudek MA, Zhao M, Smith NF, Robey RW, He P, Hallur G, Khan S, Hidalgo M, Jimeno A, Colevas AD, Messersmith WA, Wolff AC, Baker SD.
    Clin Cancer Res; 2005 Dec 01; 11(23):8503-11. PubMed ID: 16322314
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
    Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA.
    J Pharmacol Exp Ther; 2003 Mar 01; 304(3):1161-71. PubMed ID: 12604693
    [Abstract] [Full Text] [Related]

  • 40. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.
    Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T.
    J Pharm Sci; 2006 Dec 01; 95(12):2673-83. PubMed ID: 16892207
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.